Markus Y. Mapara, MD, PhD
Division of Hematology/Oncology
Dr. Mapara is Professor of Medicine at Columbia University Medical Center and the Director of the Blood and Marrow Transplantation (BMT). Dr. Mapara graduated from the University of Heidelberg Medical School/Germany, and received his post-graduate training in Internal Medicine and Hematology/Oncology at the Universities of Heidelberg and the University Medical Center Charite of the Humboldt University of Berlin in Germany. In addition, he completed a research fellowship at the Transplantation Biology Research Center of the Massachusetts General Hospital at the Harvard Medical School in Boston. As Assistant Professor of Medicine, he headed the Hematologic Intensive Care Unit and served as deputy director of the Stem Cell Transplantation unit at the University Medical Center Charité in Berlin, Germany. Before coming to Columbia, Dr. Mapara was Associate Professor of Medicine (with tenure) at the University of Pittsburgh Cancer Institute and served as the Director of the Adult Hematopoietic Stem Cell Transplantation Program.
- Blood and Marrow Stem Cell Transplantation
- Myelodysplastic Syndrome
- Cancer Care
- Bone Marrow Transplantation
- Multiple Myeloma
Choi SW, Braun T, Chang L, Ferrara JL, Pawarode A, Magenau JM, Hou G, Beumer JH, Levine JE, Goldstein S, Couriel DR, Stockerl-Goldstein K, Krijanovski OI, Kitko C, Yanik GA, Lehmann MH, Tawara I, Sun Y, Paczesny S, Mapara MY, Dinarello CA, DiPersio JF, Reddy P. Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. The Lancet Oncology. 2014;15(1):87-95. 4103793
Stenger EO, Rosborough BR, Mathews LR, Ma H, Mapara MY, Thomson AW, Turnquist HR. IL-12hi rapamycin-conditioned dendritic cells mediate IFN-gamma-dependent apoptosis of alloreactive CD4+ T cells in vitro and reduce lethal graft-versus-host disease. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2014;20(2):192-201. 3964782
Ganjoo KN, de Vos S, Pohlman BL, Flinn IW, Forero-Torres A, Enas NH, Cronier DM, Dang NH, Foon KA, Carpenter SP, Slapak CA, Link BK, Smith MR, Mapara MY, Wooldridge JE. Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity FcgammaRIIIa Patients with Previously Treated Follicular Lymphoma. Leukemia & lymphoma. 2015;56(1):42-8.
Mapara MY. Reprogramming donor T cells for adoptive immunotherapy. Immunotherapy. 2013;5(12):1287-9.
Mapara MY. The quest for the optimal conditioning regimen: some answers, more questions. Biology of blood and marrow transplantation 2013;19(9):1275-6.